Xiaxia Wu
Impact in
-
- Traditional Chinese Medicine Analysis
- Toxicology top 10%
Papers in
-
- Natural product bioactivities and synthesis 4
- Cell death mechanisms and regulation 2
-
- Traditional Chinese Medicine Analysis 3
- Co-authors
- Xiuping Chen (7 shared papers)Jin‐Jian Lu (4 shared papers)Hongwei Gao (5 shared papers)Wen Sun (5 shared papers)Xiuzhi Wang (2 shared papers)Yue Lü (2 shared papers)Ben Niu (2 shared papers)Dongfang Cheng (1 shared paper)
In The Last Decade
Xiaxia Wu
16 papers receiving 618 citations
Xiaxia Wu's Hit Papers
Peers
Comparison fields: 5 of 100
- Complementary and alternative medicine 73
- Toxicology 23
- Pharmacology 47
- Biomaterials 66
- Pharmaceutical Science 30
Countries citing papers authored by Xiaxia Wu
This map shows the geographic impact of Xiaxia Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaxia Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaxia Wu more than expected).
Fields of papers citing papers by Xiaxia Wu
This network shows the impact of papers produced by Xiaxia Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaxia Wu. The network helps show where Xiaxia Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaxia Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research Hit paper breakdown → | 2023 | 126 |
| 2 | 2018 | 118 | |
| 3 | 2017 | 116 | |
| 4 | 2016 | 57 | |
| 5 | 2018 | 50 | |
| 6 | 2018 | 42 | |
| 7 | 2018 | 33 | |
| 8 | 2018 | 27 | |
| 9 | 2020 | 25 | |
| 10 | 2017 | 20 | |
| 11 | 2021 | 4 | |
| 12 | 2023 | 4 | |
| 13 | 2024 | 3 | |
| 14 | 2021 | 2 | |
| 15 | 2024 | 1 | |
| 16 | 2023 | 1 |
About Xiaxia Wu
Xiaxia Wu is a scholar working on Molecular Biology, Complementary and alternative medicine, Infectious Diseases, Pharmacology and Pharmaceutical Science, having authored 16 papers that have together received 629 indexed citations. Recurring topics across this work include Natural product bioactivities and synthesis (4 papers), Traditional Chinese Medicine Analysis (3 papers), COVID-19 diagnosis using AI (2 papers), COVID-19 Clinical Research Studies (2 papers), Cell death mechanisms and regulation (2 papers), Intestinal Malrotation and Obstruction Disorders (1 paper), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (1 paper) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Complementary and alternative medicine (73 citations), Toxicology (23 citations), Pharmacology (47 citations), Biomaterials (66 citations) and Pharmaceutical Science (30 citations). Xiaxia Wu has collaborated with scholars based in China, Macao and Norway. Frequent co-authors include Xiuping Chen, Jin‐Jian Lu, Hongwei Gao, Wen Sun, Xiuzhi Wang, Yue Lü, Ben Niu, Dongfang Cheng, Aiping Wang and Jie Yu. Their work appears in journals such as Toxicology and Applied Pharmacology, Scientific Reports, Phytotherapy Research, Free Radical Biology and Medicine and Phytomedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.